)
The Prostate Health Index (phi) is a prostate cancer risk assessment that improves early detection of prostate cancer and can help reduce unnecessary, negative prostate biopsies. Although prostate biopsies are a common procedure, they do carry the risks associated with any invasive medical procedure, and they can also be uncomfortable for the patient. phi incorporates the results of three blood tests—PSA, free PSA and p2PSA—to calculate a phi score. The phi score provides key information about the likelihood that patients with elevated PSA have cancer, as opposed to other, more benign conditions that can also cause elevated PSA scores.
phi combines multiple prostate-specific biomarkers, providing a more accurate, specific and reliable indication of prostate health compared to traditional PSA tests1
By minimizing false positives, phi helps patients avoid unnecessary prostate biopsies, promoting patient comfort and minimizing risk while helping to reduce healthcare costs.2 If used in the correct population, phi can reduce the number of biopsies by up to 30%
phi calculated a probability of prostate cancer to aid in early detection, contributing to timely intervention, increased options for treatment and improved patient outcomes.3 When prostate cancer is detected early, a patient’s 5-year survival rate is more than 99%4
With its precision and reliability, phi fosters trust and satisfaction among those seeking clear answers about their prostate health
phi is included in the 2023 National Comprehensive Cancer Network (NCCN) Guidelines for the early detection of prostate cancer.1
A clinical study (Figure 1) comparing the treatment course of over 500 men assessed with phi to a historical control group—seen by the same urologists within the previous 24 months—showed:
Figure 1: Real world biopsies and pathological findings before and after phi
